Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections

Annals of Clinical Microbiology and Antimicrobials

Volumn 6, Issue , 2007, Pages

  Neoh, Hui Min ^a   Hori, Satoshi ^a   Komatsu, Mitsutaka ^a   Oguri, Toyoko ^a   Takeuchi, Fumihiko ^a   Cui, Longzhu ^a   Hiramatsu, Keiichi ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BACTEREMIA; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; BLOOD CULTURE; CATHETER INFECTION; DISEASE RESISTANCE; DRUG BLOOD LEVEL; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME; BLOOD; DOSE RESPONSE; DRUG EFFECT; EPIDEMIOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; PENICILLIN RESISTANCE; PRESCHOOL CHILD; RETROSPECTIVE STUDY; STAPHYLOCOCCUS AUREUS; UNIVERSITY HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTEREMIA; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDEMIOLOGY, MOLECULAR; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; MALE; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 37449021602     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-6-13     Document Type: Article

References (14)

1. Gemmell C Glycopeptide resistance in Staphylococcus aureus: Is it a real threat? J Infect Chemother 2004, 10:69-75. 10.1007/s10156-004-0307-5 15160298
2. Ruef C Epidemiology and clinical impact of glycopeptide resistance in Staphylococcus aureus Infection 2004, 32:315-327. 10.1007/ s15010-004-4124-7 15597220
3. Hiramatsu K Aritaka N Hanaki H Kawasaki S Hosoda Y Hori S Fukuchi Y Kobayashi I Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogenously resistant to vancomycin Lancet 1997, 350:1670-1673. 10.1016/S0140-6736(97)07324-8 9400512
4. Iwamoto T Kagawa Y Kojima M Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin Biol Pharm Bull 2003, 26:876-879. 10.1248/bpb.26.876 12808304
5. Horan TC Gaynes RP Surveillance of nosocomial infections Hospital epidemiology and Infection Control Philadelphia: Lippincott Williams & Wilkins Mayhall CG 3 2004:1659-702.
6. Owens WD Felts JA Spitznagel EL Jr ASA physical status classification: A study of consistency of ratings Anesthesiology 1978, 49:239-243. 10.1097/ 00000542-197810000-00003 697077
7. Howden BP Ward PB Charles PG Korman TM Fuller A du cros P Grabsch EA Roberts SA Robson J Read K Bak N Hurley J Johnson PD Morris AJ Mayall BC Grayson ML Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility Clin Inf Dis 2004, 38(4):521-528. 10.1086/381202
8. Hiramatsu K Hanaki H Ino T Yabuta K Oguri T Tenover FC Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility J Antimicrob Chemother 1997, 40:135-136. 10.1093/jac/40.1.135 9249217
9. Kloos WE Bannerman TL Staphylococcus and Micrococcus Manual of Clinical Microbiology Washington, DC: American Society for Microbiology Press Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH 6 1995:282-298.
10. Clinical and Laboratory Standards Institute (CLSI) Performance Standards for Antimicrobial Susceptibility Testing. 16th Informational Supplement CLSI document M100-S16. Wayne, PA 2006.
11. Wootton M Howe RA Hillman R Walsh TR Bennett PM Macgowan AP A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital J Antimicrob Chemother 2001, 47:399-403. 10.1093/jac/47.4.399 11266410
12. Sakoulas G Moise-Broder PA Schentag J Forrest A Moellering RC Jr Eliopoulos GM Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia J Clin Microbiol 2004, 42:2398-2402. 427878 15184410 10.1128/JCM.42.6.2398-2402.2004
13. Tanaka M Orii T Kobayashi H Hirono S Examination of factors affecting efficacy and adverse effect, for the retrospective study of vancomycin hydrochloride (VCM) Japanese Yakugaku Zasshi 2001, 121:621-629. 10.1248/ yakushi.121.621
14. Charles PG Ward PB Johnson PD Howden BP Grayson ML Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus Clin Inf Dis 2004, 38:448-51. 10.1086/381093